title: Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines.
abstract: Vaccines against human papillomavirus (HPV), the primary causative agent in cervical cancer, are licensed. This paper contains the Central European Vaccination Advisory Group (CEVAG) guidance statement on the introduction of HPV vaccines in central Europe. Eight countries currently have medical representatives on CEVAG: the Czech Republic, Estonia, Hungary, Lithuania, Poland, Romania, Slovakia and Turkey. By raising awareness and disseminating information, CEVAG aims to promote the efficient and safe use of vaccines to prevent, control and if possible eliminate infectious diseases. In January 2008, the European Centre for Disease Prevention and Control published a report entitled Guidance for the Introduction of HPV Vaccines in EU Countries. Members of CEVAG have taken the information relevant to their countries from this report and, with consideration of local issues, produced these guidance recommendations for the introduction of HPV vaccines in the CEVAG region, which may be adapted for use in individual countries.
authors.affiliation: University of Defense, Hradec Králové, Czech Republic. prymula@pmfhk.cz
authors.forename: Roman
authors.initials: R
authors.lastname: Prymula
authors.forename: Ioana
authors.initials: I
authors.lastname: Anca
authors.forename: Francis
authors.initials: F
authors.lastname: André
authors.forename: Mustafa
authors.initials: M
authors.lastname: Bakir
authors.forename: Hanna
authors.initials: H
authors.lastname: Czajka
authors.forename: Irja
authors.initials: I
authors.lastname: Lutsar
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Mészner
authors.forename: Nuran
authors.initials: N
authors.lastname: Salman
authors.forename: Pavol
authors.initials: P
authors.lastname: Simurka
authors.forename: Vytautas
authors.initials: V
authors.lastname: Usonis
mesh_terms: D000293:Adolescent; D000328:Adult; D026683:Advisory Committees; D002648:Child; D003362:Cost-Benefit Analysis; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000191:economics / Q000453:epidemiology / Q000821:virology; D053918:Papillomavirus Vaccines / Q000008:administration & dosage* / Q000191:economics; D002583:Uterine Cervical Neoplasms / Q000191:economics / Q000453:epidemiology / Q000821:virology; D014611:Vaccination / Q000191:economics; D055815:Young Adult
chemical_list: D053918:Papillomavirus Vaccines